Clinical trials: Hepatitis B Virus (HBV)
Viral Hepatitis
Continuing Medical Education to Improve Knowledge of Viral Hepatitis B-C in Primary Healthcare Workers
The purpose of study is identifying the effectiveness of 'continuing medical education' (CME) to primary healthcare worker to improve knowledge about viral hepatitis B-C
- Trial name
- NCT05207163
- Testing
- Continuing medical education
- Where
- Vietnam
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pham Ngoc Thach University of Medicine
Hepatitis B, Chronic Hepatitis B
TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B
The goal of this clinical trial is to learn if HEPLISAV-B, a vaccine that is approved to prevent hepatitis B infection in people that are not already infected, is safe in people already chronically infected with hepatitis B.
- Trial name
- BOOST-9 (NCT04843852)
- Testing
- Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Portal Hypertension
Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir
Portal hypertension is a common pathology in chronic liver disease, particularly in liver cirrhosis. Hepatitis B Virus (HBV) is one of most etiologies of liver cirrhosis in China.
- Trial name
- NCT02945956
- Testing
- Entecavir, Entecavir + Fuzheng Huayu
- Where
- 3 sites in China
- Volunteers
- 192 people
- Sponsor
- ShuGuang Hospital
Diphtheria, Tetanus
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT05952596
- Testing
- DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hepatitis B, Chronic
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
This randomized, 2 x 2 factorial, parrallel group study will compare the efficacy and safety of 48 versus 96 weeks of peginterferon alfa-2a [Pegasys], with or without entecavir, in patients with HbeAg negative chronic hepatitis…
- Trial name
- NCT01179594
- Testing
- entecavir, peginterferon alfa-2a [Pegasys]
- Sponsor
- Hoffmann-La Roche
Hepatitis B
To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.
Study population:Person with HBeAg negative CHB on TDF/ETV for more than 1 year Study design:Prospective,Interventional (single arm study) Sample size: All the patients fulfilling the inclusion criteria will be included in first…
- Trial name
- NCT03123653
- Testing
- Peg IFN 2b
- Where
- India
- Volunteers
- 118 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis B
Prevalence of HBV in Pregnancy
The most common mode of HBV transmission is materno-fetal transmission mainly during labor. This study aims to estimate the seroprevalence of HBV infection and the possible risk factors of HBV acquisition in pregnant women in…
- Trial name
- NCT05442372
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Diphtheria, Tetanus
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT06618196
- Testing
- LR20062, DTaP-HepB-IPV-Hib vaccine
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hepatitis D
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
This is an open-label, randomized, multi-center study in patients with chronic HBV and HDV co-infection.
- Trial name
- NCT05467553
- Testing
- Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide
- Where
- 2 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir
Little is known about efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic ehpatitis B patients who achieved a complete virological response to entecavir and tenofovir.
- Trial name
- NCT03236610
- Testing
- tenofovir monotherapy, tenofovir plus entecavir combination
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- Uijeongbu St. Mary Hospital
Liver Fibrosis
A Nomogram for Evaluating Significant Liver Fibrosis in Patients With Chronic Hepatitis B Virus Infection
Liver fibrosis is the key step for progression to cirrhosis and liver cancer in patients with chronic hepatitis B (CHB). It is crucial to identify significant liver fibrosis in the treatment of CHB patients.
- Trial name
- NCT05560503
- Volunteers
- 259 people
- Sponsor
- Xiangya Hospital of Central South University
Chronic Hepatitis B
COIN-B: COntrolled Interruption of Nucleos(t)Ide Analogue Treatment in Chronic Hepatitis B Infections
In this study we will prospectively stop NA in both Caucasian and non-Caucasian patients matched for gender and age, to validate the observed host and viral parameters for future roll-out of this treatment strategy.
- Trial name
- COIN-B (NCT04779970)
- Testing
- Cessation of ongoing treatment
- Where
- 26 sites in Belgium
- Volunteers
- 156 people
- Sponsor
- University Hospital, Antwerp
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis B， Chronic
Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients
A study demonstrates the non-inferiority of DA-2802 when compared with ㅍViread® in chronic hepatitis B patients
- Trial name
- NCT02967939
- Testing
- DA-2802, Viread®
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Dong-A ST Co., Ltd.
Hepatitis B
Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders
Previous studies have shown that 5-10% of Hepatitis B Virus vaccine recipients produce none or to few antibodies after a standard immunization with 3 vaccines. These individuals are defined as non-responders.
- Trial name
- NCT01451801
- Testing
- Twinrix
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Hepatitis B, Chronic
A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B
Establishment and validation of the non-invasive model to predict antiviral therapy in the gray zone of chronic hepatitis B
- Trial name
- NCT06041022
- Testing
- Exposure factors
- Volunteers
- 1,000 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatitis B, Chronic Hepatitis B
Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B
This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.
- Trial name
- NCT00412529
- Testing
- Entecavir, Telbivudine
- Where
- 8 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B
To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B
To assess whether PEG-INF (Peglyated - interferon) Add-on therapy in patients of CHB who have achieved a maintained viral suppression (HBV DNA PCR( polymerase chain reaction) <200 for last 3-6 month) with NA's can result in…
- Trial name
- RC14/055 (NCT02982837)
- Testing
- PEG-IFN & Nucleos(t)tide analogues, Nucleos(t)tide analogues
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 214 people
- Sponsor
- King Abdullah International Medical Research Center
Hepatitis B Virus
NK Cell Deregulation in HBV Patients
Natural Killer (NK) cells play a large role in the innate immune response as they are equipped to kill infected or tumor cells. They express a panel of activating and inhibitory receptors that regulate the destruction of the…
- Trial name
- LiNKeB (NCT03761875)
- Testing
- blood sample CHB patients, boold sample Control group
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Hepatitis B, Chronic
An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)
Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease.
- Trial name
- NCT01205165
- Testing
- Adefor dipivoxil
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.